REGENXBIO (RGNX) News Today $8.93 -0.08 (-0.89%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$8.95 +0.02 (+0.22%) As of 08/29/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RGNX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Vanguard Group Inc. Has $24.83 Million Stock Position in REGENXBIO Inc. $RGNXAugust 31 at 3:07 AM | marketbeat.comAlphaQuest LLC Increases Stock Holdings in REGENXBIO Inc. $RGNXAugust 29 at 4:57 AM | marketbeat.comREGENXBIO to Participate in Upcoming Investor ConferencesAugust 28, 2025 | prnewswire.comAlgert Global LLC Takes $354,000 Position in REGENXBIO Inc. $RGNXAugust 27, 2025 | marketbeat.com22NW LP Makes New $4.78 Million Investment in REGENXBIO Inc. $RGNXAugust 26, 2025 | marketbeat.comLeerink Partnrs Expects Reduced Earnings for REGENXBIOAugust 23, 2025 | marketbeat.comFY2025 EPS Estimates for REGENXBIO Decreased by AnalystAugust 23, 2025 | americanbankingnews.comREGENXBIO Inc. (NASDAQ:RGNX) Receives $28.38 Consensus Target Price from AnalystsAugust 22, 2025 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for REGENXBIO (NASDAQ:RGNX)August 21, 2025 | marketbeat.comVoss Capital LP Has $2.79 Million Position in REGENXBIO Inc. $RGNXAugust 21, 2025 | marketbeat.comREGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of "Moderate Buy" from AnalystsAugust 20, 2025 | marketbeat.comREGENXBIO Inc.: REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS IIAugust 19, 2025 | finanznachrichten.deRegenxbio announces FDA review extension for RGX-121 BLAAugust 19, 2025 | msn.comRegenxbio FDA delay ‘not a needle mover,’ says LeerinkAugust 19, 2025 | msn.comAnalyst Expectations For Regenxbio's FutureAugust 19, 2025 | benzinga.comREGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS IIAugust 18, 2025 | prnewswire.comXTX Topco Ltd Reduces Stake in REGENXBIO Inc. (NASDAQ:RGNX)August 13, 2025 | marketbeat.comAre Options Traders Betting on a Big Move in Regenxbio Stock?August 12, 2025 | msn.comREGENXBIO (NASDAQ:RGNX) Shares Pass Below 50-Day Moving Average Following Weak EarningsAugust 10, 2025 | marketbeat.comRoyal Bank Of Canada Cuts REGENXBIO (NASDAQ:RGNX) Price Target to $17.00August 10, 2025 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Downgraded to "Strong Sell" Rating by Wall Street ZenAugust 10, 2025 | marketbeat.comThese Analysts Just Made An Incredible Downgrade To Their REGENXBIO Inc. (NASDAQ:RGNX) EPS ForecastsAugust 9, 2025 | uk.finance.yahoo.comBarclays Cuts REGENXBIO (NASDAQ:RGNX) Price Target to $37.00August 9, 2025 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Given Buy Rating at Chardan CapitalAugust 9, 2025 | marketbeat.comREGENXBIO Reports Second Quarter 2025 Financial Results and Operational HighlightsAugust 7, 2025 | prnewswire.comREGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic RetinopathyAugust 7, 2025 | prnewswire.comRegenxbio Q2 2025 Earnings PreviewAugust 7, 2025 | msn.comREGENXBIO Publishes Preclinical Data Highlighting RGX-202’s Potential for Duchenne Muscular DystrophyAugust 1, 2025 | insidermonkey.comGSA Capital Partners LLP Boosts Stake in REGENXBIO Inc. (NASDAQ:RGNX)August 1, 2025 | marketbeat.comREGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational HighlightsJuly 31, 2025 | prnewswire.comREGENXBIO (RGNX) Expected to Announce Quarterly Earnings on ThursdayJuly 31, 2025 | marketbeat.comCerity Partners LLC Makes New $228,000 Investment in REGENXBIO Inc. (NASDAQ:RGNX)July 29, 2025 | marketbeat.comREGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of "Moderate Buy" from BrokeragesJuly 25, 2025 | marketbeat.comREGENXBIO Inc. (RGNX): A Bull Case TheoryJuly 24, 2025 | insidermonkey.comFY2028 EPS Estimates for REGENXBIO Raised by Leerink PartnrsJuly 21, 2025 | marketbeat.comREGENXBIO Inc. (NASDAQ:RGNX) is largely controlled by institutional shareholders who own 67% of the companyJuly 18, 2025 | finance.yahoo.comREGENXBIO Announces Publication of Preclinical Results Demonstrating ...July 11, 2025 | morningstar.comMREGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular DystrophyJuly 10, 2025 | prnewswire.comRGNX | REGENXBIO Inc. Annual Income Statement - MarketWatchJuly 6, 2025 | marketwatch.comJanney Montgomery Scott LLC Makes New Investment in REGENXBIO Inc. (NASDAQ:RGNX)July 4, 2025 | marketbeat.comAssenagon Asset Management S.A. Sells 283,399 Shares of REGENXBIO Inc. (NASDAQ:RGNX)June 16, 2025 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Stock Price Up 6.1% - What's Next?June 11, 2025 | marketbeat.comA Glimpse Into The Expert Outlook On Regenxbio Through 8 AnalystsJune 9, 2025 | benzinga.comREGENXBIO's (RGNX) Buy Rating Reaffirmed at Chardan CapitalJune 9, 2025 | marketbeat.comRegenxbio's RGX-121 Could Become The New Standard Of Care In Hunter SyndromeJune 6, 2025 | seekingalpha.comREGENXBIO updates Phase 1/2 data for Duchenne candidateJune 5, 2025 | msn.comEarly Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, LongerJune 5, 2025 | benzinga.comREGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202June 5, 2025 | prnewswire.comREGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 5, 2025 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Shares Up 13.5% - Still a Buy?June 3, 2025 | marketbeat.com Get REGENXBIO News Delivered to You Automatically Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RGNX Media Mentions By Week RGNX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RGNX News Sentiment▼1.511.11▲Average Medical News Sentiment RGNX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RGNX Articles This Week▼65▲RGNX Articles Average Week Get the Latest News and Ratings for RGNX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for REGENXBIO and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies DYN News APGE News TWST News BEAM News CDTX News IMCR News BHVN News WVE News AUPH News TVTX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RGNX) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredA Major Economic Change Is Happening NowLouis Navellier is one of Wall Street’s most respected money managers — overseeing more than $7 billion and ea...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding REGENXBIO Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share REGENXBIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
